Valiant Laboratories Ltd - 543998 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
Valiant Organics Limited, a promoter group entity of Valiant Laboratories, announced the acquisition of 1.86 crore equity shares, representing a 34.26% stake, from Dhanvallabh Ventures LLP through an off-market transaction. This move is part of a larger internal restructuring exercise.
May 20 2026 10:05:00
Valiant Laboratories Limited
Valiant Laboratories Limited announced a proposed inter-se transfer of 18.6 million equity shares (34.26% of total capital) between promoter entities Dhanvallabh Ventures LLP and Valiant Organics Limited. This internal transfer is part of a restructuring exercise by the promoter group.
May 19 2026 23:05:00
Valiant Laboratories Ltd - 543998 - Intimation Recieved Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011
Valiant Laboratories' promoter Dhanvallabh Ventures LLP is set to transfer 1.86 crore equity shares (34.26% stake) to fellow promoter entity Valiant Organics Limited. This inter-se transfer is part of a restructuring exercise by Valiant Organics Limited.
May 19 2026 23:05:00
Valiant Laboratories Ltd - 543998 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Valiant Laboratories' Board has given in-principle approval to explore potential restructuring options across the company, its holding, subsidiaries, and associates. This aims to achieve operational, organizational, and strategic synergies, including possible mergers or demergers.
May 16 2026 18:05:00
Valiant Laboratories Limited
Valiant Laboratories' board approved exploring potential restructuring options across its company, holding, subsidiaries, and associates. The initiative aims to achieve operational, organizational, and strategic synergies, ultimately unlocking long-term shareholder value.
May 16 2026 18:05:00
Valiant Laboratories Ltd - 543998 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Valiant Laboratories received a Monitoring Agency Report for Q4 FY26 confirming appropriate utilization of Rs.81.47 crore rights issue proceeds. The report noted no deviations from the stated objects, with funds largely deployed as per the offer document.
May 14 2026 20:05:00
Valiant Laboratories Limited
Valiant Laboratories received a Monitoring Agency Report for Q4 FY26, confirming that the funds raised through its Rights Issue (INR 81.46 Cr) were utilized appropriately for the stated objects, with no deviations observed. This indicates adherence to the offer document and good governance.
May 14 2026 20:05:00
Valiant Laboratories Ltd - 543998 - Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31, 2026.
Valiant Laboratories' board approved FY26 audited results. Standalone revenue grew 62.75% YoY to ₹217.04 crore, turning a net loss of ₹2.15 crore in FY25 into a net profit of ₹5.55 crore. Consolidated revenue rose 78.03% to ₹237.47 crore, but cons. net loss widened to ₹3.27 crore from ₹2.20 crore in FY25.
May 14 2026 19:05:00
Valiant Laboratories Limited
Valiant Laboratories announced the resignation of Mr. Bhanudas D. Patil, Q.C Manager and Senior Management Personnel, citing personal commitments. He will be relieved from services effective April 22, 2026.
Apr 23 2026 14:04:00
Valiant Laboratories Limited
Valiant Laboratories announced the resignation of Mr. Bhanudas D. Patil, Q.C Manager and Senior Management Personnel, citing personal commitments. He will be relieved from services effective April 22, 2026.
Apr 23 2026 14:04:00
Read More